Skip to content

Avalo Therapeutics

US · AVTX #3484 by market cap
6.76 +0.01 +0.15%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 6.79 +0.59%
After-hours 6.76 0.00%
20.756.636.762026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AVTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -63.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 16.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -123,601.7% Better than 0%
Net margin -132,642.4% Better than 0%
Return on equity -72.4% Better than 7%
Return on invested capital -72.1% Better than 4%
Momentum F

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -65.9% Better than 1%
6-month return -58.7% Better than 5%
12-month return (ex latest month) -61.1% Better than 1%
Distance below 52-week high 72.1% Better than 5%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 8.1x Better than 92%
Debt to assets 0.3% Better than 97%
Free cash flow / net income 105.3% Better than 42%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 71.4% Better than 49%
Upside to average target 284.6% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.89%
1M -45.31%
3M -65.89%
6M -58.50%
YTD -62.78%
1Y -61.89%
3Y -67.25%
5Y -99.89%

Key statistics

Price & volume

Prev close
6.75
Open
6.65
Day range
6.61 - 7.03
Avg price
6.77
Volume
1.18M
Turnover
7.98M
Amplitude
6.22%
52-week range
6.53 - 24.27

Valuation

P/E
-1.16
P/E (TTM)
-2.99
P/B
0.90
EPS
-5.84
Net profit
-337.69M
Net assets
436.56M

Share structure

Market cap
390.88M
Float cap
269.59M
Shares out
57.82M
Float shares
39.88M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 1% of range
6.53 24.27

72.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.47M net over the window

Short interest

Shares short
8.91M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Avalo Therapeutics (AVTX)?

Avalo Therapeutics last traded at 6.76. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Avalo Therapeutics's market cap?

About 390.88M.

What is the P/E ratio of Avalo Therapeutics?

The trailing twelve-month P/E is -2.99. The Valuation tab shows it against the stock's own five-year range.

Does Avalo Therapeutics pay a dividend?

Avalo Therapeutics does not currently pay a regular dividend.

Is Avalo Therapeutics a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 26.00, which implies 284.6% upside from the current price. This is not investment advice.

What is Avalo Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Avalo Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Avalo Therapeutics discussion 0 comments

Add a comment